oncology CRO - strategic site relationships

Linical Accelovance and MMP Strategic Relationship Benefits Sponsors

Linical Accelovance and the Midwest Melanoma Partnership (MMP) have a strategic agreement to facilitate clinical trial research and development. The focus of MMP is to "facilitate the sharing of ideas, clinical trials and resources in an effort to improve the diagnosis, treatment and long-term care of melanoma patients." Through this strategic relationship we are able to provide access to the top investigative sites and medical professionals in the US working in the area of melanoma. Specifically, this relationship entails:

  • Unparalleled Knowledge through membership consisting of 19 prestigious academic and community based sites (including: Mayo Clinic, University of Illinois-Chicago, Roswell Park Cancer Institute, University of Michigan, Duke University, and University of Wisconsin)
  • Expedited Start-up as Linical Accelovance and MMP have structures in place with many institutions that best positions your study for rapid study startup. Some academic institutions can start within 90 days (IRB approval and contract approval)
  • Enhanced Recruitment and Patient Access based on MMP sites seeing over 25% of all metastatic melanoma cases in the US
  • Direct Alignment with Key Opinion Leaders
This partnership significantly enhances and differentiates Linical Accelovance's Oncology CRO services.  By collaborating with Linical Accelovance and MMP, we can accelerate and significantly advance your melanoma targeted investigative product.  Your organization will therefore achieve its critical development milestones on-time and improve the lives of people afflicted by this disease.   To contact us and speak with the Linical Accelovance and MMP team, simply complete the "Contact Our Team" form.  

For more information on Midwest Melanoma Partnership, please visit their website.